In the NEW era of universal adult hepatitis B vaccination1,*
Heplisav-B is the first and only adult hepatitis B vaccine that provides series completion with just 2 doses in 1 month1-3
HEPLISAV-B NDC#: 43528-0003-05
See the CDC recommendation for hepatitis B vaccination
Read Full articleThe CDC recommends hepatitis B vaccination for all adults aged 19-59 and adults aged ≥60 with hepatitis B risk factors. Adults aged ≥60 without risk factors may receive hepatitis B vaccination.1
Adults eligible for influenza vaccines calculated from population aged 18+ in 2022; adults eligible for shingles vaccines calculated using adults turning 50 years old in 2022, adults aged >50 who are unvaccinated based on CDC coverage rates, and immunocompromised adults aged 19-49; adults eligible for pneumonia vaccines included adults aged 65+ and at-risk adults aged 18-64 excluding smokers, patients with chronic heart disease, and patients who are immunocompromised; adults eligible for hepatitis B vaccination calculated using US census data published in 2018, CDC coverage data, and risk factor analyses.4
IN A STUDY of adults aged 19+ did not receive all 3 doses5
Don’t delay the switch
EXPLORE INTERCHANGEABILITYIn a survey of 1002 adults in the United States who use a pharmacy and are likely to receive a vaccination at a pharmacy, 71.26% (n=714) preferred 2 doses over 1 month, 19.26% (n=193) had no preference, and 9.48% (n=95) preferred 3 doses over 6 months.4
HEPLISAV-B NDC#: 43528-0003-05
Give your pharmacy the benefits of 2-dose HEPLISAV-B2,6-9
Looking for more information on HEPLISAV-B?
Get ResourcesHEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.
Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.
The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).
Please see full Prescribing Information.
References: 1. Centers for Disease Control and Prevention. Recommended adult immunization schedule for ages 19 years or older, United States, 2022. Accessed April 14, 2022. https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf 2. HEPLISAV-B [package insert]. Emeryville, CA: Dynavax Technologies Corporation; 2020. 3. Haber P, Schillie S. Hepatitis B. In: Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Public Health Foundation; 2021:143-164. 4. Data on file. Dynavax Technologies Corporation; 2022. 5. Williams WW, Lu PJ, O’Halloran A, et al. Surveillance of vaccination coverage among adult populations—United States, 2015. MMWR Surveill Summ. 2017;66(11):1-28. doi:10.15585/mmwr.ss6611a1 6. Nelson JC, Bittner RC, Bounds L, et al. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health. 2009;99(suppl 2):S389-S397. doi:10.2105/AJPH.2008.151332 7. Dynavax Technologies Corporation. FDA Advisory Committee Briefing Document: HEPLISAV-B™ (Hepatitis B Vaccine [Recombinant], Adjuvanted). Presented at: Meeting of the Vaccines and Related Biological Products Advisory Committee; July 28, 2017; Silver Spring, MD. 8. Engerix-B [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2018. 9. Bruxvoort K, Slezak J, Huang R, et al. Association of number of doses with hepatitis B vaccine series completion in US adults. JAMA Netw Open. 2020;3(11):e2027577. doi:10.1001/jamanetworkopen.2020.27577
HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.